Tag: Alpha-glucosidase inhibitor

Acarbose is a pseudotetrasaccharide alpha-glucosidase inhibitor isolated from fermentation cultures of the actinobacterium Actinoplanes utahensis and subsequently produced at industrial scale by Actinoplanes sp. SE50/110. The compound competitively and reversibly inhibits the brush border alpha-glucosidases (maltase-glucoamylase, sucrase-isomaltase) of the small intestinal epithelium and, at higher concentrations, pancreatic alpha-amylase, thereby delaying the hydrolysis of complex carbohydrates and oligosaccharides to absorbable monosaccharides and producing a dose-dependent reduction in postprandial glycemic excursion without direct stimulation of insulin secretion [1, 2]. Acarbose received its first regulatory approval in Germany in 1990 and was approved by the United States Food and Drug Administration in 1995 under the trade name Precose; it is marketed in over 100 countries worldwide as Glucobay (Bayer) and under multiple generic names. The compound is one of the most widely prescribed antidiabetic agents in East Asia, where postprandial hyperglycemia contributes disproportionately to overall glycemic burden in carbohydrate-rich dietary patterns. The pharmacokinetic profile of acarbose is dominated by its topical mechanism of action within the gastrointestinal lumen. Less than 2 percent of an oral dose is absorbed as intact drug; the remainder is degraded by intestinal bacteria and digestive enzymes in the distal small intestine and colon, producing at least 13 metabolites, of which one (4-methylpyrogallol and its conjugates) accounts for the majority of systemically absorbed radioactivity [3, 4]. Systemic exposure is therefore minimal, and the pharmacodynamic effect is determined by intraluminal drug concentration relative to the enzyme targets rather than by plasma pharmacokinetics. The compound is not metabolized by hepatic cytochrome P450 enzymes and has negligible renal clearance of intact drug. Clinical evidence for acarbose in type 2 diabetes mellitus is extensive. Pivotal registration trials demonstrated reductions in glycated hemoglobin (HbA1c) of 0.5 to 0.8 percentage points and reductions in postprandial glucose of 40 to 60 mg/dL at oral doses of 50 to 100 mg three times daily with meals [5, 6]. The UKPDS 44 substudy confirmed sustained glycemic efficacy over 3 years as add-on therapy to sulfonylurea or metformin [7]. The STOP-NIDDM trial (Study to Prevent Non-Insulin-Dependent Diabetes Mellitus) in 1368 subjects with impaired glucose tolerance demonstrated a 25 percent relative risk reduction in progression to type 2 diabetes and a 49 percent relative risk reduction in cardiovascular events over 3.3 years of treatment, though the cardiovascular endpoint was secondary and based on a small number of events [8, 9]. The larger ACE trial (Acarbose Cardiovascular Evaluation) in 6522 Chinese patients with coronary heart disease and impaired glucose tolerance found no reduction in major adverse cardiovascular events over 5 years of follow-up but confirmed an 18 percent relative risk reduction in incident diabetes [10]. Beyond the established antidiabetic indication, acarbose has attracted substantial recent interest as a longevity intervention. The National Institute on Aging Interventions Testing Program (ITP), a rigorous, multi-site, genetically heterogeneous mouse study, demonstrated that acarbose at 1000 ppm in chow extended median lifespan by approximately 22 percent in males and 5 percent in females, with corresponding increases in maximum lifespan [11, 12]. The sex-differential effect parallels the male-preferential lifespan extension observed with 17-alpha-estradiol and nordihydroguaiaretic acid in the same program. Mechanistic investigations have linked the longevity effect to increased delivery of undigested starch to the colonic microbiome, resulting in elevated production of short-chain fatty acids (butyrate, propionate, acetate), shifts in microbial community composition toward Bacteroidetes-dominant profiles, and reductions in circulating insulin-like growth factor 1 (IGF-1) and fasting insulin [13, 14]. Combination of acarbose with rapamycin in the ITP produced additive lifespan extension (median lifespan increases of 28 percent in females and 34 percent in males when initiated at 9 months of age), supporting the hypothesis that the two compounds operate through complementary pathways [15]. The principal adverse effects of acarbose are gastrointestinal: flatulence (reported in up to 78 percent of patients at initiation), diarrhea, and abdominal discomfort, all reflecting the mechanism of action (bacterial fermentation of undigested carbohydrate in the colon) and typically diminishing with continued therapy and gradual dose titration [16]. Rare hepatotoxicity, presenting as asymptomatic transaminase elevation or, in isolated cases, clinically apparent hepatocellular injury, has been reported in postmarketing surveillance and is generally reversible upon discontinuation [17]. This monograph reviews the chemistry, biosynthesis, and structural pharmacology of acarbose; the mechanism of alpha-glucosidase and alpha-amylase inhibition at the molecular level; the comprehensive pharmacokinetic record; the clinical evidence base across antidiabetic, diabetes prevention, cardiovascular, and longevity indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal; and a comparative assessment of five alternative glucose-lowering or longevity-relevant compounds against acarbose on five competency standards.